雷文尼布:在急性白血病治疗中开启了一个新时代
David A Martínez-Gamboa1, Justin Kaner2
1Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.
Trends in cancer
|January 25, 2025
概括
雷文梅尼布在急性白血病中改善了生存率和缓解. 更新的数据证实了疗效,导致FDA对复发性或耐火性KMT2A重组急性白血病的批准.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 急性白血病,特别是KMT2A重新排列的类型,存在重大治疗挑战.
- 复发或耐药性疾病状态往往有不良预后.
研究的目的:
- 报告来自AUGMENT-101试验的更新的第二阶段结果.
- 评估revumenib在急性白血病患者中的疗效.
主要方法:
- AUGMENT-101试验研究了急性白血病患者的revumenib.
- 从第二阶段的结果分析了更新后的数据,对其进行了更长的随访.
主要成果:
- 雷文尼布证明了整体存活率 (OS) 的改善.
- 观察到显著的完全缓解 (CR) /CR与部分血液恢复 (CRh) 率.
- 随着更长时间的随访,更新的数据证实了这些积极的结果.
结论:
- 雷文梅尼布是治疗急性白血病的有效方法.
- 更新的数据支持revumenib的临床益处.
- 雷文尼布已获得FDA对KMT2A-r急性白血病的批准.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


